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Introduction: Acute heart failure (AHF) is characterized by inadequate cardiac output (CO), congestive symptoms,
poor peripheral perfusion and end-organ dysfunction. Treatment often includes a combination of diuretics, oxygen,
positive pressure ventilation, inotropes and vasodilators or vasopressors. Lactate is a marker of illness severity but is
also an important metabolic substrate for the myocardium at rest and during stress. We tested the effects of half-molar
sodium lactate infusion on cardiac performance in AHF.
Methods: We conducted a prospective, randomised, controlled, open-label, pilot clinical trial in 40 patients fulfilling
two of the following three criteria for AHF: (1) left ventricular ejection fraction <40%, (2) acute pulmonary oedema or
respiratory failure of predominantly cardiac origin requiring mechanical ventilation and (3) currently receiving vasopressor
and/or inotropic support. Patients in the intervention group received a 3 ml/kg bolus of half-molar sodium lactate over
the course of 15 minutes followed by 1 ml/kg/h continuous infusion for 24 hours. The control group received only a
3 ml/kg bolus of Hartmann’s solution without continuous infusion. The primary outcome was CO assessed
by transthoracic echocardiography 24 hours after randomisation. Secondary outcomes included a measure of
right ventricular systolic function (tricuspid annular plane systolic excursion (TAPSE)), acid-base balance, electrolyte and
organ function parameters, along with length of stay and mortality.
Results: The infusion of half-molar sodium lactate increased (mean ± SD) CO from 4.05 ± 1.37 L/min to 5.49 ± 1.9 L/min
(P < 0.01) and TAPSE from 14.7 ± 5.5 mm to 18.3 ± 7 mm (P = 0.02). Plasma sodium and pH increased (136 ± 4 to 146 ± 6
and 7.40 ± 0.06 to 7.53 ± 0.03, respectively; both P< 0.01), but potassium, chloride and phosphate levels decreased. There
were no significant differences in the need for vasoactive therapy, respiratory support, renal or liver function tests, duration
of ICU and hospital stay or 28- and 90-day mortality.
Conclusions: Infusion of half-molar sodium lactate improved cardiac performance and led to metabolic alkalosis in AHF
patients without any detrimental effects on organ function.
Trial registration: Clinicaltrials.gov NCT01981655. Registered 13 August 2013.Introduction
Critically ill patients develop acute heart failure (AHF)
de novo or experience exacerbation of chronic heart fail-
ure due to coronary ischaemia, arrhythmias, medication
noncompliance, worsening renal function, primary infec-
tion or other illness [1]. Symptoms are usually related to* Correspondence: mareknalos@gmail.com
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end-organ dysfunction [2]. Standard treatment options
include oxygen, positive pressure ventilation, diuretics,
vasodilators, inotropes and vasopressors, despite their
potential disadvantages and side effects [3]. Vasodilators
are associated with tachyphylaxis and hypotension, and
inotropes and vasopressors cause tachycardia, arrhyth-
mias, coronary ischaemia and worse overall survival in
AHF patients [4]. The promising inotropic agent levosi-
mendan has not convincingly led to superior outcomestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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noninvasive, increases myocardial contraction by a me-
chanism of action independent of cAMP activation and
has the potential to improve organ function and patient
outcomes [8].
Blood lactate is regarded as a marker of illness severity,
and increased plasma lactate levels are common in AHF
and acute coronary syndromes [9-11]. Although some evi-
dence derived from animal experiments suggests that lac-
tate has direct negative effects on myocardium [12], data
reported more recently support the role of lactate as a pre-
ferred oxidative substrate in stressed myocardium [13-16].
Overall lactate metabolism in severe cardiogenic shock
has been found not to be significantly altered, and half-
molar sodium lactate infusion increased cardiac output
(CO) while a negative fluid balance was maintained in pa-
tients after coronary artery bypass grafting [17,18].
Herein we report the results of our prospective, open-
label, pilot, randomised, controlled clinical trial of half-
molar sodium lactate infusion to improve cardiac function
in critically ill patients with acute heart failure and re-
duced left ventricular ejection fraction (LVEF).
Methods
The study was conducted between December 2009 and
November 2012 in the Department of Intensive Care
Medicine at Nepean Hospital, University of Sydney,
Australia. The Sydney West Area Health Service Ethics
Committee approved the study (HREC/09/NEPEAN/4) in
accordance with the 1964 Declaration of Helsinki and
its later amendments. Written informed consent was
obtained from the patients or their next of kin prior to en-
rolment. Adult patients over 18 years of age were pro-
spectively screened and considered eligible if two of three
criteria for AHF were met: (1) LVEF ≤40%; (2) acute pul-
monary oedema or respiratory failure of predominantly
cardiac origin requiring mechanical ventilation, including
noninvasive ventilation; and (3) currently receiving ino-
tropes and/or vasopressors. The exclusion criteria were
pregnancy, hypernatremia >145 mmol/L, hypertrophic ob-
structive cardiomyopathy, uncorrected severe valvular
heart disease, third-degree heart block, sustained ventricu-
lar tachycardia, cardiac tamponade, septic shock, acute re-
spiratory distress syndrome, moribund patients, presence
of major diseases with a poor prognosis (such as end-stage
cancer, end-stage liver failure (Child-Pugh score III or IV),
end-stage (dialysis-dependent) renal failure, and likely to
receive haemodialysis and/or filtration within 6 hours of
enrolment) and acute liver failure (defined as international
normalised ratio of 3) unrelated to warfarin use.
Study protocol
Following study enrolment, patients were randomised
to receive either half-molar sodium lactate (Kalsolac;Aguettant Santé SA, Lyon, France), denominated the
lactate group, or Hartmann’s solution (Compound So-
dium Lactate Solution; Baxter Australia, Old Toongab-
bie NSW, Australia), classified as the control group.
Randomisation was carried out in blocks of variable size
in sequentially numbered, opaque, sealed envelopes pro-
vided by an independent statistician. After baseline param-
eters were recorded and transthoracic echocardiography
(TTE) was performed, patients were given an intravenous
bolus of 3 ml/kg actual body weight (ABW) of the
assigned fluid according to randomisation over the course
of 15 minutes. A continuous infusion of half-molar so-
dium lactate at 1 ml/kg/h ABW for 24 hours was then in-
fused in the lactate group. To prevent potentially harmful
fluid overload, no additional study fluid was infused in the
control group. The Scientific Committee of the local Eth-
ics Committee mandated this aspect of the protocol. Both
groups received standard therapy for AHF according to
best practice, which included a combination of inotropes,
vasopressors, vasodilators, diuretics, intraaortic balloon
counterpulsation and mechanical ventilation as required.
Patients had TTE performed 24 and 48 hours after enrol-
ment, except for those who died or were discharged from
the ICU. Arterial blood gas analysis was performed at
baseline, after the initial study fluid bolus and together
with other laboratory and vital sign parameters at 6, 12, 24
and 48 hours after enrolment. These laboratory examina-
tions included fluid balance, electrolytes, full blood count
and renal and liver function tests. All patients were
followed up for up to 90 days.
Echocardiography
Qualified sonographers or clinicians performed TTE using
ultrasound systems equipped with tissue Doppler (Vivid i,
Vivid q or Vivid 7; GE Healthcare, Oslo, Norway). LVEF
was estimated on the basis of apical two- and four-
chamber views according to Simpson’s formula as recom-
mended by the American Society of Echocardiography
[19]. CO was obtained by multiplication of stroke volume
(SV) by heart rate (HR) in the left ventricular outflow tract
(LVOT) using the Doppler method. SV was determined as
follows: π × (LVOT diameter ÷ 2)2 × Velocity time integral
(VTI) of the blood flow signal in the LVOT. The LVOT
diameter was obtained from the parasternal long axis, and
the LVOT VTI was determined from the apical five-
chamber view using pulsed wave Doppler (PWD). Tricus-
pid annular plane systolic excursion (TAPSE) in the apical
four-chamber view was recorded to assess right ventricu-
lar systolic function. Early mitral inflow velocity (E) was
measured by PWD at the tip of the mitral valve during
diastole, and tissue Doppler imaging–derived early dia-
stolic motion velocity (E′) and systolic motion of the
mitral annulus (averaged medial and lateral) by tissue
Doppler imaging (SmTDI) were obtained by placing the
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tricular septum and lateral wall in the apical four-chamber
view. E′ and SmTDI from both locations were averaged as
recommended previously [20]. A qualified cardiologist and
intensivist (RP), who was blinded to treatment assignment,
reviewed and measured offline all TTE parameters as appro-
priate. Intra- and interobserver variability from a random
sample of ten patients were calculated.
Endpoints
The primary study outcome was CO at 24 hours after
study entry, which was measured by TTE as described
above. Secondary outcome parameters included SmTDI,
E/E′ ratio and TAPSE, overall fluid balance, blood pres-
sure, acid-base status, electrolytes, renal and liver func-
tion tests, need for mechanical ventilation (including
noninvasive), ICU and hospital lengths of stay and 28-
and 90-day mortality.
Statistical analysis
Data are expressed as mean ± standard deviation (SD).
Between-group and within-group differences due to
treatment (lactate vs. control) were assessed by two-way
repeated-measures analysis of variance and Fisher’s exact
test for qualitative data (that is, number of additional
treatments used). In cases where significant intra- or in-
tergroup differences were present, pairwise post hoc ana-
lyses were performed by using Student’s t-test. The
significance level was set at 0.05 and adjusted for mul-
tiple comparisons by the Bonferroni correction method.
To adjust for baseline imbalances and the unequal
amount of intravenous fluid in the study groups, the ‘re-
gression to the mean’ effects and analysis of covariance
(ANCOVA) were carried out using a linear model con-
taining primary outcome as the dependent variable, with
treatment as a dummy variable with baseline CO and 24-
hour fluid balance used as the covariates. Time to events
data were analysed using Kaplan-Meier statistics with sur-
vival compared using a logrank test. This trial was a pilot
study, so no formal sample size calculation was possible.
An arbitrary number of 40 patients was chosen.
Results
From among the 194 screened patients, 41 were rando-
mised (Figure 1). One patient randomised to the lactate
group was excluded from the analysis because the treating
physician deemed the patient unsuitable prior to any inter-
vention. The analysis thus included 40 patients: 19 in the
lactate group and 21 in the control group. The baseline
patient characteristics are presented in Table 1. Echocar-
diograms for all three time points were not available for
one patient in the lactate group and for two patients in the
control group, and thus these patients were excluded from
further analysis of echocardiographic parameters.Haemodynamics
The mean arterial blood pressure remained unchanged
throughout the study period in both groups (Table 2).
The mean CO was lower in the lactate group at baseline
(4.05 ± 1.37 L/min vs. 4.72 ± 1.3 L/min), but this difference
was not significant. There was no change in mean CO over
time in the control group (4.96 ± 1.21 L/min at 24 hours
and 4.76 ± 1.58 L/min at 48 hours). At the end of the 24-
hour period, CO significantly increased in the lactate group
(5.49 ± 1.9 L/min; P < 0.01) and remained higher than at
baseline at 48 hours (4.87 ± 2.38 L/min; P = 0.026). The im-
provement in CO remained significant even after adjusting
for the baseline imbalance by ANCOVA (Table 3). The
temporal change in individual CO over time is presented
in Figure 2. The intra- and interobserver variability of CO
measurements were 5.9% and 7.2%, respectively. When the
components of CO were analysed separately, SV changes,
but not HR changes, were responsible for the increase in
CO. Similarly, the right ventricular systolic function
(TAPSE) was unchanged in the control group but
improved in the lactate group (P = 0.02) (Table 2). The
SmTDI and E′ values were not significantly different at
any time point in either group, although there was a trend
toward increased SmTDI in the lactate group at 24 hours.
Although E/E′ was unchanged over 24 hours in the lactate
group (14.4 ± 6.8 to 15.2 ± 7.6), it was reduced (17.3 ± 8.3
to 13.5 ± 4.7; P = 0.03) in the control group, suggesting re-
duction in left atrial pressure (Table 3). There were no sig-
nificant intergroup differences in the concomitant use of
vasoactive and inotropic therapy or in the use of intraaor-
tic balloon counterpulsation, although fewer patients in
the lactate group required vasopressor support at 24 hours.
More patients were invasively ventilated in the lactate
group than in the control group (Table 4).Acid-base status
There were no significant changes in any of the acid-base
parameters in the control group apart from significant in-
creases in bicarbonate levels and base excess (BE) at
48 hours. In the lactate group, pH increased from 7.4 ±
0.06 to 7.45 ± 0.05, bicarbonate from 23.3 ± 3.3 to 25.9 ±
4.1 mmol/L, BE from −0.3 ± 4.1 to 2.7 ± 4.2 mmol/L and
lactate from 2.4 ± 2.3 to 4.8 ± 2.0 mmol/L (all P < 0.01)
within 15 minutes of half-molar sodium lactate solution
bolus. The pH, bicarbonate and BE continued to rise over
the 24-hour period (all P < 0.01). Once the half-molar so-
dium lactate infusion ceased, pH, bicarbonate and BE de-
clined, but they remained higher than either baseline or
the control group at 48 hours. Plasma lactate remained el-
evated during the infusion; however, the mean lactate at
24 hours was similar to baseline and declined further, so
that it was lower than in the control group at 48 hours
(Table 5).
Did not meet inclusion criteria (n = 48)
Met exclusion criteria (n = 89)
Declined participation (n = 16 ) 
Unable to locate family (n = 7 )
Assessed for eligibility
(n = 194 )
Randomized (n = 41)
Allocated to intervention (n = 20)
One excluded due to treating physician 
refusal
TTE study not available in one patient      
(died within 24 h)
Allocated to control group (n = 21)
TTE study not available in two patients 
(one died within 24 h, one discharged out 
of ICU before 48h) 
Lost to follow-up (n = 0) Lost to follow-up (n = 0)
Analyzed (n = 19) Analyzed (n = 21)
Figure 1 Flowchart illustrating study protocol for selecting and randomising patients. The number of screened, excluded, randomised and
analysed patients are given.
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There were significant changes in electrolyte levels in the
lactate group. The sodium level increased from 136 ±
4 mmol/L at baseline to 146 ± 6 mmol/L at 24 hours (P <
0.01). We also noted a significant decrease in levels of po-
tassium (4.2 ± 0.7 to 3.3 ± 0.4 mmol/L; P < 0.01), chloride
(104 ± 7 to 98 ± 9 mmol/L; P < 0.01) and phosphate (1.23 ±
0.46 to 0.98 ± 0.40 mmol/L; P = 0.04), despite clinically
driven supplementation. There were no significant changes
in electrolyte levels in the control group (Table 6).
Fluid balance
The fluid balance in the first 24 hours was 1,296 ±
1,633 ml in the lactate group versus 845 ± 1,421 ml in
the control group. The fluid balance was −339 ±
1,453 ml in the controls and 230 ± 991 ml in the lactate
group from 24 to 48 hours. Once adjusted for the vol-
ume of study fluid, the mean fluid balance was 586 ml in
the control group and −843 ml in the lactate group at
24 hours, and it was −598 ml and −1,909 ml in the con-
trol and lactate groups, respectively, at 48 hours. We
found no correlation between fluid balance and the
change in SV in the lactate group and a slightly negativecorrelation in the control group at 24 hours. After
adjusting for fluid balance by ANCOVA, the results still
showed strong support for a treatment effect of lactate,
with the lactate group exhibiting an estimated CO of
0.91 L/min more, on average, than the control group
(P = 0.011) (Table 3).
Other organ function, length of stay and mortality
There were no significant differences in other organ
functions between the groups, although serum creatinine
(Table 4) tended to be lower in the lactate group. Like-
wise, there was no significant difference between the
groups regarding the ICU and hospital length of stay or
28-day mortality (five in the lactate group vs. four in the
control group) or 90-day mortality (five in each group).
Discussion
The main finding of this randomised controlled trial is that
hypertonic half-molar sodium lactate infusion (3 ml/kg
over 15 minutes followed by 1 ml/kg/h for 24 hours) in-
creased CO in critically ill patients with AHF. The effect
was related to a significant increase in SV rather than
HR. We also observed improvement in right ventricular
Table 1 Baseline demographic variables, aetiology of acute
heart failure and related chronic premorbid conditionsa
Patient characteristics Control group Lactate group
Age (years) 69.9 ± 9.8 67.4 ± 14.6
Sex (male/female) 17/4 13/6
Weight (kg) 86.5 ± 19.6 79.2 ± 22.3
APACHE II score 18.5 ± 6.9 18.6 ± 5.3
LVEF (%) 27.1 ± 10.3 27.2 ± 8.1
Bilirubin (μmol/L) 15 ± 13 20 ± 25
ALT (IU/L) 489 ± 1,026 525 ± 928













aADHF = Acute decompensated heart failure; ALT = Alanine aminotransferase;
APACHE II = Acute Physiology and Chronic Health Evaluation II; CCF = Chronic
congestive heart failure; HT = Hypertension; IHD = Ischaemic heart disease;
LVEF = Left ventricular ejection fraction; NSTEMI = Non-ST-segment elevation
myocardial infarct; STEMI = ST-segment elevation myocardial infarct. bSome
patients had more than one condition present. Data are expressed as mean ±
SD unless indicated otherwise.
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half-molar sodium lactate was safe and well tolerated, but
it had a marked effect on acid-base status and plasma elec-
trolytes. The total amount of intravenous sodium lactate
(13.5 mmol/kg/24 h, which is roughly equal to three-Table 2 Evolution of haemodynamic and selected transthorac
Time points MAP HR SV
Baseline
Control 78 ± 15 97 ± 23 50.6 ± 13
Lactate 77 ± 16 95 ± 24 49 ± 19.4
24 hours
Control 78 ± 12 91 ± 14 53.3 ± 13
Lactate 79 ± 17 95 ± 15 59.6 ± 20
48 hours
Control 77 ± 15 91 ± 15 52.3 ± 16
Lactate 85 ± 18 89 ± 17 54.1 ± 26
aE/E′ = Ratio of early peak diastolic transmitral Doppler flow velocity to early peak diastoli
HR = heart rate (beats/min); MAP=Mean arterial pressure (mmHg); SmTDI = Systolic moti
(cm/s); SV = Stroke volume; TAPSE = Tricuspid annular plane systolic excursion (mm). bP<fourths of endogenous daily lactate production in resting
humans) was associated with modest metabolic alkalosis
and hypernatraemia as well as mild hypochloraemia,
hypokalaemia and hypophosphataemia.
Under normal conditions, the main energy supply for
the heart is the oxidation of fatty acids, whereas other
nutrients such as glucose lactate and amino acids con-
tribute to myocardial ATP generation in varying propor-
tions. At rest, approximately 10% to 40% of energy is
derived from pyruvate formed either by glycolysis or the
conversion of lactate. Although fatty acids have higher
yields of ATP per molecule, the ATP yield per oxygen
molecule utilized is 5% to 10% better with lactate and
glucose, respectively [21]. During exercise, β-adrenergic
stimulation, elevated afterload and fast pacing, both lac-
tate uptake by the myocardium and its use as metabolic
fuel increase [17,22-24]. Lactate may even exceed glucose
as an oxidative substrate in the presence of elevated
plasma lactate levels [21]. In rats with ischaemia-induced
chronic heart failure, maximum lactate influx into isolated
cardiomyocytes was increased by 250% and the lactate
transporter MCT1 protein level was increased by 260%,
suggesting increased utilization of lactate [25]. Of rele-
vance is that sodium lactate infusion has been reported to
increase CO in anaesthetized pigs after surgery, whereas
whole-body oxygen utilization tended to increase, suggest-
ing lactate oxidation [26]. Studies in patients have demon-
strated that exogenous half-molar sodium lactate infusion
is well tolerated after major elective surgery and increases
CO in patients after cardiac bypass surgery [27,28].
Although we do not provide direct evidence of lactate
oxidation by the heart, the relatively low plasma lactate
levels, together with an increase in SV and CO in the
lactate group, suggest myocardial lactate metabolism.
Previous studies have documented lactate oxidation in
patients with cardiogenic shock while receiving a short-
term sodium lactate infusion (2.5 mmol/kg for 15 mi-
nutes) [17]. The effects of sodium lactate on acid-baseic echocardiography parameters during the study perioda
TAPSE SmTDI E/E′
.7 16.3 ± 5 6.0 ± 0.02 17.3 ± 8.3
14.7 ± 5.5 5.84 ± 0.02 14.4 ± 6.8
.5 16 ± 5.5 6.53 ± 0.02 13.5 ± 4.7a
b 18.3 ± 7b 7.0 ± 0.04 15.2 ± 7.6
17.1 ± 5.7 6.5 ± 0.02 13.8 ± 5.7a
.5 18.1 ± 7.8a 6.2 ± 0.03 15.9 ± 9.7
c tissue Doppler velocity of the mitral annulus (averaged medial and lateral);
on of the mitral annulus (averaged medial and lateral) by tissue Doppler imaging
0.05 and cP< 0.01 compared to baseline values. Data are expressed as mean ± SD.
Table 4 Evolution of concomitant treatment and
interventions during the study perioda
Time points Intervention Control Lactate
Baseline Vasopressors 9 9
Vasopressor dose (μg/kg/min) 0.04 ± 0.06 0.07 ± 0.1
Levosimendan (0.1 μg/kg/min) 5 4
Dobutamine 1 0
IABP 2 4
Invasive ventilation 10 14
Noninvasive ventilation 5 1
24 hours Vasopressors 7 3
Vasopressor dose (μg/kg/min) 0.03 ± 0.05 0.03 ± 0.1
IABP 2 4
Invasive ventilation 9 10
Noninvasive ventilation 5 0
48 hours Vasopressors 2 3
Vasopressor dose (μg/kg/min) 0.01 ± 0.03 0.04 ± 0.1
IABP 2 3
Invasive ventilation 4 9
Noninvasive ventilation 1 2
aIABP = Intraaortic balloon counterpulsation device. Vasopressors are
noradrenaline or adrenaline. Levosimendan (12.5 mg) was administered at
0.1 μg/kg/min over the course of 24 hours during the study period. Infusions
were always started prior to study enrolment. All data are expressed as
number of patients, except for vasopressor dose, for which data are expressed
as mean ± SD.
Table 3 Analysis of covariance dataa
Covariate β SE 95% CI P-value
Constant 0.79 0.86 −0.97 to 2.55 0.365
Treatment 0.91 0.34 0.22 to 1.57 0.011
Baseline CO 0.71 0.12 0.47 to 0.95 <0.001
Fluid balance −0.000047 0.00097 −0.00025 to 0.00015 0.627
aβ: Regression coefficient; CI: Confidence interval; CO: Cardiac output. F-value
for the model = 12.12. P < 0.001.
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tients with AHF also suggest increased lactate metabolism.
Others have reported an increased rate of gluconeogenesis
and lactate oxidation during sodium lactate infusion
[16,18]. Nevertheless, the effects of sodium lactate on CO
may not be fully attributable to lactate oxidation by the
myocardium as the resulting metabolic alkalosis per se
may lead to improved myocardial function [28]. As the
lactate anion is metabolized in the cells, the sodium is ex-
pelled, thus increasing strong ion difference in the intersti-
tial space and plasma and causing metabolic alkalosis
according to the Stewart concept [18,27,29]. However, al-
kalosis has an effect on systemic vascular resistance and
endogenous production of catecholamines, making the ef-
fect of alkalosis on CO variable, and we believe smaller,
compared to the utilization of lactate [30-32]. Neverthe-
less, in our present study, it was impossible to distinguish
between the contribution of sodium lactate metabolism
and resulting metabolic alkalosis because the latter follows
the former. It is unlikely that hypernatraemia, hypokal-
aemia or hypophosphataemia led to the marked increase
in SV, TAPSE and CO in our patients with AHF.
Limitations
We conducted a pilot, single-centre, open-label clinical
trial. Despite the relatively small number of randomisedFigure 2 Graphs depict the temporal changes in individual
patients’ cardiac output over the course of 24 and 48 hours.patients, we demonstrate a significant effect of half-
molar sodium lactate on cardiac function, a finding simi-
lar those reported by others [18,26]. We did not utilize
continuous measurement of CO in our study, because
this is not a universal practice in our ICU. Instead, we
used comprehensive echocardiographic assessment by
skilled operators, and a qualified reporter blinded to
treatment group assignment measured the echocardio-
graphic parameters. An important limitation of this
study is the imbalance in the amount of fluid infusion
between the two groups, resulting in possible confound-
ing effects of positive fluid balance. However, the
ANCOVA shows that, after adjusting for the nonsignifi-
cant baseline imbalance in CO and the fluid balance
over the course of 24 hours, CO still significantly in-
creased in the group that received lactate. Despite the
increase in CO, there was no effect on length of ICU or
hospital stay, mechanical ventilation or survival; how-
ever, the study was not sufficiently powered for those
endpoints.
Conclusions
The findings of our present study regarding increased
SV, CO and right ventricular systolic function in critic-
ally ill patients with AHF receiving half-molar sodium
Table 5 Evolution of acid base parameters in arterial blood during the study perioda
Time point pH PaCO2 PaO2 HCO3
− BE Lactate
Baseline
Control (n = 21) 7.37 ± 0.1 40 ± 13 98 ± 33 22.8 ± 4.9 −1.7 ± 5.6 1.4 ± 0.5
Lactate (n = 19) 7.40 ± 0.06 36 ± 9 103 ± 28 23.3 ± 3.3 −0.3 ± 4.1 2.4 ± 2.3
Post-bolus
Control (n = 21) 7.37 ± 0.09 40 ± 9 91 ± 19 23.1 ± 5.1 −1.01 ± 5.7 2 ± 1.4
Lactate (n = 19) 7.45 ± 0.05b,c 38 ± 8 95 ± 30 25.9 ± 4.1b 2.7 ± 4.2 4.8 ± 2.0b
6 hours
Control (n = 20) 7.38 ± 0.06 42 ± 9 93 ± 27 24.1 ± 4.8 −0.7 ± 5.3 1.6 ± 1.2
Lactate (n = 19) 7.49 ± 0.04b,c 43 ± 5b 87 ± 24 32.5 ± 4.8b,c 8.9 ± 4.5b,c 2.9 ± 1.0c
12 hours
Control (n = 19) 7.38 ± 0.07 42 ± 10 95 ± 37 24.3 ± 4.7 −0.2 ± 5.2 1.4 ± 0.6
Lactate (n = 19) 7.51 ± 0.04b,c 47 ± 5b 82 ± 24 37.1 ± 5.3b,c 12.9 ± 4.6 3.1 ± 1.6c
24 hours
Control (n = 19) 7.41 ± 0.07 38 ± 11 84 ± 20 23.9 ± 5.4 −0.9 ± 5.8 1.5 ± 1.0
Lactate (n = 18) 7.53 ± 0.03b,c 51 ± 7b,c 81 ± 26 41.4 ± 6.3b,c 16.8 ± 4.8b,c 2.3 ± 0.8c
48 hours
Control (n = 18) 7.42 ± 0.03 42 ± 9 87 ± 28 26.9 ± 5.6b 2.8 ± 5.3b 1.6 ± 0.9
Lactate (n = 18) 7.47 ± 0.03b 48 ± 4b 95 ± 42 34.2 ± 4.1b,c 9.6 ± 4.2b,c 1.2 ± 0.5b
aBE = Base excess (mmol/L); HCO3
− = Bicarbonate (mmol/L); PaCO2 = Partial pressure of carbon dioxide (mmHg); PaO2 = Partial pressure of oxygen (mmHg).
bP < 0.01
compared to baseline values and cP < 0.01 for intergroup comparison. Data are expressed as mean ± SD.
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detrimental to myocardial function in the critically ill
and support the view that endogenous lactate may be an
important substrate for myocardium during periods of
physiological stress [33]. We suggest that infusion ofTable 6 Evolution of biochemistry parameters during the stud
Time point Na+ K+
Baseline
Control (n = 21) 137 ± 5 4.3 ± 0.8
Lactate (n = 19) 136 ± 4 4.2 ± 0.7
6 hours
Control (n = 20) 137 ± 5 4.2 ± 0.6
Lactate (n = 19) 141 ± 5b,c 3.8 ± 0.4d
12 hours
Control (n = 19) 137 ± 6 4.3 ± 0.6
Lactate (n = 19) 143 ± 5b,e 3.6 ± 0.4b,e
24 hours
Control (n = 19) 138 ± 5 4.3 ± 0.5
Lactate (n = 18) 146 ± 6b,e 3.3 ± 0.4b,e
48 hours
Control (n = 18) 138 ± 7 4.3 ± 0.4
Lactate (n = 18) 144 ± 6b,e 3.8 ± 0.5
aCl − = Plasma chloride concentration (mmol/L), Crea = Plasma creatinine concentra
sodium concentration (mmol/L), P = Plasma phosphate concentration (mmol/L). bP <
comparison. Data are expressed as mean ± SD.half-molar sodium lactate may improve CO in AHF pa-
tients with reduced LVEF; however, its clinical use may
be limited in patients with alkalaemia or hypernatraemia
or in those with severely compromised liver and renal
function.y period
Cl− P Crea
104 ± 5 1.46 ± 0.62 175 ± 107
104 ± 7 1.23 ± 0.46 146 ± 123
104 ± 4 1.36 ± 0.54 174 ± 124
100 ± 7b 0.95 ± 0.50b 138 ± 126
104 ± 5 1.40 ± 0.58 186 ± 135
99 ± 7b 0.96 ± 0.45d 134 ± 123
104 ± 4 1.30 ± 0.49 168 ± 133
98 ± 9b 0.98 ± 0.40d 136 ± 128
102 ± 4 1.22 ± 0.33 156 ± 130
103 ± 6 1.15 ± 0.41 129 ± 119
tion (μmol/L), K+ = Plasma potassium concentration (mmol/L), Na+ = Plasma
0.01 compared to baseline, cP < 0.05, dP < 0.05, eP < 0.01 intergroup
Nalos et al. Critical Care 2014, 18:R48 Page 8 of 9
http://ccforum.com/content/18/2/R48Key messages
 Infusion of half-molar sodium lactate (13.5 mmol
over 24 hours) improved cardiac performance, chal-
lenging the dogma that lactate per se is detrimental
to myocardial function.
 Our results support an important role of lactate in
cardiac metabolism during periods of critical illness.
 Half-molar sodium lactate can be thought of as an
alternative inotrope in AHF patients with reduced
LVEF who possess organ function sufficient for
lactate metabolism.
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